This application is a National Stage Entry entitled to and hereby claiming priority under 35 U.S.C. §§ 365 and 371 to corresponding PCT Application No. PCT/GB2018/050308, filed Feb. 2, 2018 entitled “Phased Convective Operation”, which in turn claims priority to G.B. Patent Application No.: 1701740.1, filed Feb. 2, 2017, entitled the same. The disclosures of the above applications are incorporated herein by reference in their entireties.
The present invention relates to convective operation of a blood treatment device, and in particular to a convective operation method providing user control and potential for tailoring.
Patients suffering from reduced kidney function rely on external blood treatments to remove harmful waste substances that build up in their blood over time. One of the most common methods of treatment is haemodialysis. An example of haemodialysis is set out in the applicant's previous application WO2015/022537.
Haemodialysis typically involves two networks of fluid passageways running adjacent to one another in a counter-current flow arrangement. Blood is passed through one set of tubules and dialysate is passed through the other. The pH and osmotic potential of the dialysate is adapted such that waste compounds built up in the blood diffuse from the blood into the dialysate through a semi-permeable membrane which separates the blood and dialysate sides of the network of fluid passageways.
Haemodialysis provides a method of gradually removing waste materials with a molecular weight from 50 to 60000 Daltons from the blood by diffusion, minimising fatigue to the patient. However, there are some disadvantages associated with haemodialysis.
One disadvantage of haemodialysis is that medium molecular weight molecules (mMVV) dissolved in the blood (for example β-2 microglobulin), which are typically between 1000 and 15000 Daltons, are difficult to remove completely from the blood using haemodialysis. It can take a long time to reduce the levels of these substances in the blood to acceptable levels, which may not be convenient for a patient. One other disadvantage of haemodialysis is that molecules can become attached to the semi-permeable membrane, causing a film to build up on the membrane over time. This is detrimental to the operation of the device.
An alternative approach to remove waste molecules from the blood is to use a form of convective operation, such as haemodiafiltration.
Classically, haemodiafiltration involves administering sterile dialysate to the blood either by employing a large hydrostatic potential to force sterile dialysate across a semi-permeable membrane into the blood or by directly adding it to the blood; and then pulling the sterile dialysate, complete with dissolved waste products, back across the semi-permeable membrane for subsequent disposal. This type of blood treatment is not limited by diffusion, as sterile dialysate is allowed to mix directly with the blood and returned to the dialysate by a process termed “solute drag”.
One known haemodiafiltration method of directly adding dialysate to the blood is controlled by infusing the blood side of the dialyser with sterile solution at a constant flow rate. However, increased patient monitoring may be necessary, and this type of treatment may not suit all patients.
An example of haemodiafiltration is also set out in the applicant's previous application WO2015/022537, the contents of which are incorporated herein by reference.
Known methods may not allow much control over, or tailoring of, the infusion. Known methods may require extra haemodiafiltration dialysate preparation steps, extra haemodiafiltration dialysate filtration and sterilisation steps, and an additional pump or pumps to move the dialysate independently of the blood pump or pumps.
There is therefore a need for improvements in blood treatment methods and devices.
According to a first aspect of the invention, there is provided a blood treatment device comprising: a dialyser; an inlet pump assembly configured to deliver a first volume of dialysate from a dialysate source to the dialyser in an inlet pump cycle having a dialysate delivery stroke; an outlet pump assembly configured to remove a second volume of dialysate from the dialyser and deliver the dialysate away from the dialyser in an outlet pump cycle having a dialysate removal stroke; and a control system configured to operate the inlet pump assembly in the inlet pump cycle, and configured to operate the outlet pump assembly in the outlet pump cycle, wherein for each inlet pump cycle there is a corresponding outlet pump cycle, wherein each inlet pump assembly dialysate delivery stroke has a commencement time t1 and a termination time t2, each outlet pump assembly dialysate removal stroke has a commencement time t3 and a termination time t4, and either: each dialysate removal stroke commencement time t3 is after the respective corresponding dialysate delivery stroke commencement time t1 and before the respective corresponding dialysate delivery stroke termination time t2; or each dialysate delivery stroke commencement time t1 is after the respective corresponding dialysate removal stroke commencement time t3 and before the respective corresponding dialysate removal stroke termination time t4.
This arrangement has several advantages over known arrangements. This arrangement may allow for a hybrid of the technical effects of haemodialysis and haemodiafiltration, by allowing for convective operation for part of a pumping cycle. In contrast to known haemodiafiltration, the present arrangement allows for peaks in fluid pressure during part of the pumping cycle, as well as net fluid flow across the dialyser membrane in two directions. This may allow for effective filtration of medium molecular weight molecules without patient fatigue that may result from haemodiafiltration. Repeated peaks in pressure in the dialyser that can result from this method also allow the dialyser membrane to be cleaned, preventing build-up of molecules on the dialyser membrane.
The time between the dialysate delivery stroke commencement time t1 and the dialysate removal stroke commencement time t3 may be a fraction ϕ of either the dialysate delivery stroke (when t3 is between t1 and t2) or the dialysate removal stroke (when t1 is between t3 and t4), the fraction ϕ being between 0.01 and 0.99. Preferably, the fraction ϕ is between 0.05 and 0.95, further preferably the fraction ϕ is between 0.1 and 0.8. This feature may allow for optimal convective operation.
Each dialysate delivery stroke may be the same duration as its corresponding dialysate removal stroke. The device may be configured such that the first and the second volumes of dialysate are substantially the same. This may facilitate easy fluid monitoring.
The control system may be configured such that the first volume of dialysate is delivered to the dialyser in one inlet pump cycle. The control system may be configured such that the second volume of dialysate is removed from the dialyser in one outlet pump cycle.
The inlet pump assembly may comprise an inlet pump and the outlet pump assembly may comprise an outlet pump, each of the inlet pump and the outlet pump being defined in part by a flexible membrane, the flexible membrane being independently operable between an open position and a closed position for each of the inlet and the outlet pumps. This arrangement may allow for a simple and efficient design of the blood treatment device.
The inlet pump cycle may commence from an inlet pump open position. The outlet pump cycle may commence from an outlet pump closed position.
The dialyser may have an inlet fluidly connected to the dialyser inlet pump and an outlet fluidly connected to the dialyser outlet pump. The inlet pump assembly may comprise a dialyser inlet valve and the outlet pump assembly may comprise a dialyser outlet valve.
The inlet pump and the outlet pump may both be operable to deliver a volume of dialysate from a dialysate source to the dialyser and remove a volume of dialysate from the dialyser. This arrangement may allow for pump-swapping, wherein the inlet pump is operated as an outlet pump, and the outlet pump may operate as an inlet pump. Pump-swapping has the advantage of compensating for any differences in pump size and speeds. For example, even if the inlet pump and the outlet pump are designed to be the same size as each other, manufacturing tolerances may prevent the pumps from being exactly the same size. Such a size difference may result in a flow imbalance over time, which may be corrected for by pump swapping. The control system may be configured to alternate the pump responsible for delivering dialysate to the dialyser and the pump responsible for removing spent dialysate from the dialyser after a given number inlet pump of cycles. The number of inlet pumping cycles may be two or more inlet pumping cycles. Pump-swapping after a minimum of two or more inlet pumping cycles may be an optimal operational mode. The pre-determined fraction ϕ may be maintained during pump swapping, such that it is the same before and after pump swapping.
The inlet pump and the outlet pump may be arranged to pump a predetermined volume of dialysate.
The inlet pump and the outlet pump may be formed on a disposable cartridge. The dialyser inlet valve and the dialyser outlet valve may be formed on the disposable cartridge. The pumps and valves on the disposable cartridge may be operated by actuation of the flexible membrane by negative and/or positive air pressure.
There may be provided a machine comprising the blood treatment device as defined above. Selective application of the negative/positive air pressure to actuate the pumps and valves on the disposable cartridge may be effected by a pneumatic pump. Each pump or valve may have an associated pneumatic pump on the machine which receives the cartridge. The control system may control the operation of the respective pneumatic pumps. The control system may be a microprocessor which controls the pneumatic pumps electronically. The control may be effected wirelessly.
According to a second aspect of the invention, there is provided a method of operating a blood treatment device, the method comprising the steps of: providing a blood treatment device, the blood treatment device comprising a dialyser, an inlet pump assembly, an outlet pump assembly, and a control system; operating the inlet pump assembly in an inlet pump assembly cycle to deliver a first volume of dialysate from a dialysate source to the dialyser, each inlet pump assembly cycle including a dialysate delivery stroke having a commencement time t1 and a termination time t2; operating the outlet pump assembly in an outlet pump assembly cycle to remove a second volume of dialysate from the dialyser and deliver the second volume of dialysate away from the dialyser, each outlet pump assembly cycle including a dialysate removal stroke having a commencement time t3, wherein for each outlet pump assembly cycle there is a corresponding inlet pump assembly cycle; such that each dialysate removal stroke commencement time t3 is after the respective corresponding dialysate delivery stroke commencement time t1 and before the respective corresponding dialysate delivery stroke termination time t2.
The time between the dialysate delivery stroke commencement time t1 and the dialysate removal stroke commencement time t3 may be a fraction ϕ of the dialysate delivery stroke, the fraction ϕ being between 0.01 and 0.99. The fraction ϕ may be between 0.05 and 0.95. The fraction ϕ may be between 0.1 and 0.8. This feature may allow for optimal convective operation.
Each dialysate delivery stroke may be the same duration as its corresponding dialysate removal stroke. The first and the second volumes of dialysate may be substantially the same. This may facilitate easy fluid monitoring.
The first volume of dialysate may be delivered from a dialysate source to the dialyser in one inlet pump cycle. The second volume of dialysate may be removed from the dialyser and delivered away from the dialyser in one outlet pump assembly cycle.
The inlet pump assembly may comprise an inlet pump, and the outlet pump assembly may comprise an outlet pump, each of the inlet pump and outlet pump being defined by a flexible membrane, the membrane being operable between an open position and a closed position for each of the inlet and the outlet pumps. The inlet pump cycle may commence from an inlet pump open position. The outlet pump cycle may commence from an outlet pump closed position. The dialyser may have an inlet fluidly connected to the dialyser inlet pump assembly and an outlet fluidly connected to the dialyser outlet pump assembly. The inlet pump assembly may comprise a dialyser inlet valve and the outlet pump assembly comprises a dialyser outlet valve. The inlet valve and the outlet valve may each be independently operable between an open position and a closed position. Each of the inlet pump and the outlet pump may be defined in part by a flexible membrane, the flexible membrane being independently operable between an open position and a closed position for the inlet and the outlet valves.
The inlet pump assembly and outlet pump assembly may both be operable to deliver a volume of dialysate from a dialysate source to the dialyser and remove a volume of dialysate from the dialyser and deliver said dialysate to the drain.
The method may further comprise the step of alternating the pump responsible for delivering dialysate to the dialyser and the pump responsible for removing spent dialysate from the dialyser after a given number of cycles. The number of pumping cycles may be two or more pumping cycles. This arrangement has the advantages outlined above.
The fraction ϕ may be actively changed depending on dialyser outlet pressure. The fraction ϕ may be controlled by closed loop control. This may reduce the need for manual monitoring of the device.
Embodiments of the present invention will now be described, by non-limiting example only, with reference to the accompanying drawings, in which:
The following detailed description and figures provide examples of how the present invention can be implemented and should not be seen as limiting examples, rather illustrations of how the various features of the convective operation device disclosed herein can be used. Other optional variations will be evident upon a reading of the following description in light of the figures.
Referring to
The dialyser has an inlet 20 for receiving clean dialysate solution and an outlet 22 for removing spent dialysate solution from the dialyser 12. The dialyser also has an inlet 24 for receiving untreated blood from the peristaltic pump 16 and an outlet 26 for returning processed blood to the patient. The dialyser 12 is typically provided in a substantially upright orientation, in use, with the patient's blood flowing longitudinally through the dialyser 12 from the blood inlet 24 to the blood outlet 26. The dialysate solution inlet 20 and dialysate solution outlet 22 are configured to be orientated substantially orthogonal to the blood inlet 24 and blood outlet 26, and configured to provide a counter-flow. Dialysate solution is circulated through the hemodialysis machine at a fluid flow rate typically in the range of 500 ml/min to 800 ml/min for approximately four hours.
The dialysis system defines a fluid circuit including a cartridge 30 as will now be described. The cartridge 30 is a consumable component in the hemodialysis machine described.
The cartridge 30 is formed from an acrylic plastic such as SG-10 and has a machine side and a patient side. The cartridge 30 defines pump chambers which are closed by respective diaphragms, formed from, for example, DEHP-free PVC, to define respective pumps. In this embodiment, each diaphragm is part of a single, common sheet of material applied to the machine side of the cartridge 30. The individual diaphragms are operable by pneumatic pressure applied thereto.
A series of flow paths are formed in the cartridge 30 for carrying dialysate solution constituted from water, bicarbonate solution and acid solution. The flow paths are located between the sheet of material closing the machine side of the cartridge 30 and a further sheet of the same material closing the patient side of the cartridge 30.
In use, the variation of pressure applied to the flexible diaphragm of each pump chamber is controlled by conventional valving. A pressure source applies either a positive or negative pressure to one side of the diaphragm of each pump chamber, as required, to pump fluid through the fluid paths in the cartridge 30, in a circuit defined by a plurality of valves.
The valves of the cartridge 30 are conventional diaphragm valves defined by respective openings in the cartridge 30 and closed by respective flexible diaphragms. Each valve is operable by applying a negative pressure to the diaphragm to open the valve and applying a positive pressure to the diaphragm to close the valve. The diaphragm of each valve is part of the single, common sheet of material applied to the machine side of the cartridge 30. The valves are opened and closed according to a flow control strategy, as will become apparent.
The machine side of the cartridge 30 abuts a pump driver (not shown) comprising a platen having a plurality of recessed surfaces, each recessed surface substantially corresponding in geometry and volume to a pump chamber defined in the cartridge 30. Each recessed surface has a fluid port connectable with a source of positive fluid, typically, pressure and, with a source of negative fluid pressure via a valve.
A cartridge fluid pump and corresponding platen chamber are shown in
The cartridge 30 has two main functions, preparation of dialysate solution and flow balance. Each function is performed by a separate part of the cartridge as illustrated in
The cartridge 30 is provided with a plurality of connections to and from the cartridge 30 as described below. A first inlet port 38, from hereon referred to as the water inlet port, defined in the machine side of the cartridge 30 receives purified water from a purified water supply 31 such as a reverse osmosis water supply.
A first outlet port 42, from hereon referred to as the water outlet port, defined in an edge of the cartridge 30 directs the purified water to a first dialysate solution constituent which, in the illustrated embodiment shown in
A second inlet port 50, from hereon referred to as the bicarbonate inlet port, defined in the same edge of the cartridge 30 as the water outlet port 42 receives purified water mixed with the bicarbonate 46.
A third inlet port 82, from hereon referred to as the acid inlet port, defined in the opposite edge of the cartridge 30 to the water outlet port 42 and bicarbonate inlet port 50 receives a second dialysate solution constituent which, in the illustrated embodiment shown in
A second outlet port 104, from hereon referred to as the clean dialysate solution outlet port, is defined in the same edge of the cartridge as the water outlet port 42 and the bicarbonate inlet port 50. The clean dialysate outlet port 104 directs clean dialysate solution to the dialyser 12.
A fourth inlet port 106, from hereon referred to as the spent dialysate solution inlet port, is defined in the same edge of the cartridge 30 as the water outlet port 42, bicarbonate inlet port 50 and clean dialysate outlet port 104. The spent dialysate solution inlet port 106 receives spent dialysate solution from the dialyser 12.
A third outlet port 122, from hereon referred to as the drain port, is defined in the same edge of the cartridge as the acid inlet port 82. The drain port 122 directs spent dialysate solution out of the cartridge 30.
The membrane pump cartridge comprises first and second source valves 205, 206, first and second pumps 207, 216 and first and second pump chambers 208, 218, first and second dialyser inlet valves 209, 217 and first and second dialyser outlet valves 213, 215.
The vacuum pump array and platen comprises a platen having a pattern of circular depressions which correspond in position and size to the valves and pumps on the pump cartridge. In the figure, these are numbered 100 higher than the membrane pump features.
Each depression has an aperture at the base thereof which is in fluid communication with an associated vacuum pump. Each vacuum pump, shown in broken lines as they sit on the rear face of the platen, is numbered 100 higher than the respective associated platen feature.
All of the vacuum pumps are connected to a control system 500. The control system 500 is a microprocessor which operates the vacuum pumps 405-419 in a manner so as to effect either convective operation or haemodialysis as described below. The connection to the pumps may be wired or wireless. Wireless connection options include IR, Bluetooth or WIFI, amongst others.
The dialysate is produced elsewhere on the cartridge by mixing acid and bicarbonate compounds with a set volume of water provided by a reverse osmosis machine which has been sterilised. This forms the source of dialysate 327 used by the pump and valve arrangement 201.
All valves and pumps are independently operable. In one embodiment, all pumps 207, 216 and all valves 205, 206, 211, 209, 213, 215, 217, 219 are independently operable by pneumatic pressure applied to the flexible membrane.
By selectively operating the vacuum pumps, the control system controls the opening and closure of the valves as well as actuation of the first and second pumps. The microprocessor control system is programmable to operate the valves in a variety of different configurations. Based on the programming of the controller, the controller will communicate with each of the valves or means for operating the valves, so that each valve may be opened and closed independently based on the programming entered into the controller by the user, skilled operator or programme instructions.
The apparatus described can be used in different modes: simple haemodialysis mode and phased convective operation mode. The device described above is adapted such that each mode can be actively controlled. Such control can prevent accidental use of the wrong mode at any given time, and allow tailoring of the convective operation method.
After each use, the hemodialysis machine requires sanitising to prevent contamination of a patient's bloodstream during subsequent dialysis sittings. The removable cartridge 30, as described above, is usually disposed of after each sitting. In one embodiment of the invention, the cartridge 30 is sanitised to allow re-use in subsequent dialysis sittings. Such sanitisation may include steps of operating the device as it would be used during haemodialysis or convective operation. In one sanitisation method, dialysate may be caused to flow through the device in the same way or a similar way to how dialysate would flow during haemodialysis, haemodiafiltration or phased convective operation.
The pumping cycle of the first mode of operation of the arrangement 201 begins with closure of the first and second dialyser inlet valves 209, 217 and the first and second dialyser outlet valves 213, 215. The first source valve 205 and the first drain valve 219 are opened, the second source valve 206 and second drain valve 211 are closed. The first pump 207 is then operated to draw dialysate 327 from the dialysate source 203 into the first pump chamber 208 of the first pump 207 and the second pump 216 is operates to expel dialysate 327 within the second pump chamber 218 of the second pump 216 into the drain 221. Accordingly, the dialysate 327 in the dialysate source 203 is drawn into the first pump chamber 208 by the negative pressure created as the membrane of the first pump chamber 208 is drawn away from the pump chamber by vacuum means in the dialysis machine (not shown). The dialysate 327 in the second pump chamber 218 is subjected to a positive pressure as the membrane in the second pump 216 is forced into the second pump chamber 218 thus driving the dialysate out through the open first drain valve 219 to be discarded.
In the next stage of the pump cycle, the first dialyser inlet valve 209 and the first dialyser outlet valve 215 are opened and the first source valve 205 and the first drain valve 219 are closed. The first pump 207 is then actuated to expel the dialysate 327 from within the first pump chamber 208 into the dialyser (not shown) and the second pump 216 is actuated to pull spent dialysate 327 from the dialyser (not shown) into the second pump chamber 218. In this step, the dialysate 327 in the first pump chamber 208 has a positive pressure applied to it as the membrane is forced down into the first pump chamber 208 thereby forcing the dialysate 327 through the dialysis circuit and into the dialyser. In the dialyser, dialysate 327 is passed in a typically counterflow arrangement to the blood of the patient and waste products diffuse across the dialyser membrane into the dialysate 327 via diffusion. The movement of the dialysate 327 through the dialyser and into the second pump chamber is assisted by a negative pressure generated by the membrane of the second pump chamber which is retracted by the vacuum means on the dialysis machine, operated by the device's controller. These two stages are repeated and then, in the third stage of the pump cycle, the first dialyser inlet valve 209 and first dialyser outlet valve 215 are closed, the first drain valve 219 is opened and second pump 216 actuated to expel the spent dialysate 327 from the second pump chamber 218 into the drain 221. Accordingly, after the completion of this step, both pump chambers 208, 218 are empty.
In the fourth step of the cycle, the first drain valve 219 is closed and the second source valve 206 is opened in order to allow the second pump 216 to draw dialysate from the source 203 into the second pump chamber 218. In the fifth step, with the second pump chamber 218 now filled, the second dialyser inlet valve 217 the second dialyser outlet valves 213 are opened and the second source valve is closed. The second pump 216 is actuated to expel the dialysate in the second pump chamber 218 into the dialyser (not shown) and the first pump 207 is actuated to draw dialysate from the dialyser into the first pump chamber 208. This allows the same operation as was carried out in the first and second steps to proceed but with the roles of the pumps 207, 216 swapped around. Thus any small discrepancies between the volumes of the two pump chambers 208, 218 are cancelled out.
The fourth and fifth steps are repeated and finally, the second dialyser outlet valve 213 and second dialyser inlet valve 217 are closed, the second drain valve 211 and second source valves are opened and the first pump 207 is operated to expel the dialysate from the first pump chamber 208 into the drain 221.
In contrast to the haemodialysis mode described above, phased convective operation does not operate with pump movements that are directly synchronised with each other.
There are two main ways in which phased convective operation can be achieved. In the first, referred to herein as “phase-delay convective operation” mode, each dialysate removal stroke commencement time t3 is after the respective corresponding dialysate delivery stroke commencement time t1 and before the respective corresponding dialysate delivery stroke termination time t2. Phase-delay convective operation is analogous to (but not the same as) pre-dilution in haemodiafiltration. In the second, referred to herein as “phase-advance convective operation” mode, each dialysate delivery stroke commencement time t1 is after the respective corresponding dialysate removal stroke commencement time t3 and before the respective corresponding dialysate removal stroke termination time t4. Phase-advance convective operation is analogous to (but not the same as) post-dilution in haemodiafiltration.
For simplicity, phase-delay convective operation (that is analogous to pre-dilution in haemodiafiltration) will be described in detail. It should be understood that the second option will have a corresponding technical effect as the first option. The second option will be described briefly with reference to
One aim of phased convective operation is to achieve peaks in pressure in the dialyser, so that convective operation occurs repeatedly but for short amounts of time (i.e. not during a whole pump action).
Phase-delay convective operation achieves this by blocking or inhibiting fluid from leaving an outlet 22 of the dialyser 12, while fluid is being caused to flow through the dialyser inlet 20. As fluid continues to flow through the inlet 20, the outlet 22 is opened.
The time difference between fluid commencing flow through the inlet 20 and fluid commencing flow through the outlet 22 is controlled, such that the dialysate delivery stroke commencement time and the dialysate removal stroke commencement time are always separated by a time delay δt.
It should be understood that the equations below represent an example of how the pump assemblies can be operated to produce the required phase delay. It should be understood that the pump assemblies can be operated in a variety of different ways to achieve the required phase delay effects.
Each inlet pump delivery stroke (and by definition inlet pump cycle) commences at time t1=ta+x tip, each outlet pump cycle commences at a time t3=ta+x top, wherein ta is the commencement time of the first inlet pump cycle, tb is the commencement time of the first outlet pump cycle, x is an integer corresponding to the number of pump cycles, tip is the time for each full inlet pump cycle, and top is the time for each full outlet pump cycle.
In phase-delay convective operation, the time delay δt is governed by a pre-determined fraction ϕ of the delivery stroke time (t2−t1), where:
δt=ϕ(t2−t1)
wherein t2 is the delivery stroke termination time.
The pre-determined fraction ϕ may also govern the delay δt between the delivery stroke termination time t2 and the removal stroke termination time. This causes a pressure drop in the dialysate side of the dialyser 12, such that dialysate and dissolved medium molecular weight waste particles can be dragged back across the dialyser semi-permeable membrane and be removed.
The time delay δt between delivery stroke commencement time and the removal stroke commencement time may equally be different to the time delay between the delivery stroke termination time and the removal stroke commencement time.
Time point t1 to time point t2 denotes one inlet pump assembly dialysate delivery stroke. Time point t1 to the following time point t1 denotes one inlet pump cycle.
In
At time point t1 of
At time point t3 of
From point t2 to point t1, the inlet pump 207 is actuated to draw dialysate from a source into the inlet pump 207. No dialysate is caused to flow into the dialyser 12 during this time. This may be by means of actuation of a valve to close an inlet to the dialyser 12. From point t2 to t1, the outlet pump 216 is actuated to force dialysate from the outlet pump 216 to a location away from the dialyser 12, which may be a drain or another part of the machine circuit. No dialysate is caused to flow out of the dialyser 12 during this time. This may be by means of actuation of a valve to close an outlet to the dialyser 12.
The inlet pressure line in
The outlet pressure line in
As shown by
The solid line can be represented with the function described above, wherein:
Each inlet pump delivery stroke (and by definition inlet pump cycle) commences at a time t1;
t1(x)=ta+x tip,
The dashed line can also be represented with the function described above, wherein:
Each outlet pump cycle commences at a time t3;
t3(x)=tb+x top,
and wherein ta is the commencement time of the first inlet pump cycle, tb is the commencement time of the first outlet pump cycle, and x is an integer corresponding to the number of pump cycles.
In haemodialysis, there is no delay between t1 and t3.
Considering the delay function:
δt=ϕ(t2−t1)
wherein t2 is the delivery stroke termination time.
The pre-determined fraction in haemodialysis must be zero. In haemodialysis, there is no pre-determined fraction ϕ, and no resulting net peaks in pressure.
As shown in
The inlet pressure line in
At point t1 of
At point t3 of
The outlet pressure line in
In contrast to haemodialysis illustrated in
Similar to haemodialysis, the solid line can represented with the function described above, wherein:
Each inlet pump delivery stroke (and inlet pump cycle) commences at a time t1;
t1(x)=ta+x tip,
The dashed line can also be represented with the function described above, wherein:
Each outlet pump removal stroke (and outlet pump cycle) commences at a time t3;
t3(x)=tb+x top,
and wherein ta is the commencement time of the first inlet pump cycle, tb is the commencement time of the first outlet pump cycle, and x is an integer.
With phase-delay convective operation there is a delay between t1 and corresponding t3.
Considering the delay function:
δt=ϕ(t2−t1)
wherein t2 is the delivery stroke termination time.
The pre-determined fraction in phase-delay convective operation is a number between 0 and 1. In phase-delay convective operation, there is a pre-determined fraction ϕ, and net peaks in pressure, as shown in
Any net pressure (peak or trough) corresponds to a driving pressure in the dialyser, which can force particles across the semi-permeable membrane in the dialyser. A net pressure peak results in dialysate being forced across the semi-permeable membrane from the dialysate side to the blood side of the dialyser. This forcing may clear the membrane of particles which may build up on the membrane. A net trough in pressure results in dialysate being dragged across the semi-permeable membrane from the blood side to the dialysate side of the dialyser. The dialysate being dragged back across the semi-permeable membrane will drag with it medium molecular weight waste molecules.
As outlined above with reference to
As described previously, idealised phase-delay convective operation is plotted on a graph having axes of inlet pressure 702, and outlet pressure 704 against time 706. This may correlate directly to inlet flow rate and outlet flow rate, which in practice can be measured. The square-shaped peak 725 in the solid line is due to the fourth pulsatile pump cycle of the inlet pump, in particular due to an inlet pump delivery stroke. The square-shaped peak 735 in the dashed line is due to the fourth outlet pump removal stroke, which may be due to pulsatile opening and closing of an outlet valve 213, or opening and closing of an outlet pump.
This worked example considers the time factors of the outlet pump when the inlet pump time factors are known, and when the pre-determined fraction is known.
As an example, the first pump cycle of the inlet pump 207 (ta) starts after 1 second, i.e. ta=1. Also by way of example, each inlet pump cycle takes two seconds (one second to draw fluid in from a source, and one second to force fluid out to a drain or circuit).
Given that:
t1=ta+x tip,
And given that for this example,
t1=1+2x
For the fourth pump cycle (shown in
t1=1+2*4
t1=9 seconds
Therefore point 721 (t1) of
As stated above, the delay function is:
δt=ϕ(t2−t1)
Accordingly:
δt=1ϕ
In this worked example, ϕ is set at 0.2, however as stated previously, various possible values of ϕ are possible.
This gives a delay function value of:
δt=1*0.2
δt=0.2
Point 731 (t3) of
Finding point 731 (t3) using the outlet pump cycle time function gives the same result:
t3=tb+x top,
t3=(ta+δt)+x top
t3=(1+0.2)+4*2
t3=9.2
During the 0.2 seconds at the start of the first pump cycle (point 721 (t1) to 731 (t3)), the pressure in the dialyser is peaked. In theory, in the idealised example given, dialysate will transfer from the dialysate side of the dialyser to the blood side of the dialyser in this first 0.2 seconds. In the following 0.8 seconds of the first pump cycle (point 731 (t3) to 740 (t2)), there is no net transfer of fluid across the semi-permeable membrane of the dialyser. In the following 0.2 seconds (point 740 (t2) to 733), dialysate will transfer from the blood side of the dialyser to the dialysate side of the dialyser. For the following 0.8 seconds of the first pump cycle (point 733 to 742), there is no net transfer of fluid across the semi-permeable membrane of the dialyser.
As shown by the worked example given above (which is given as an example of what the functions represent and should not be seen as limiting values), a key factor in the relation between the inlet pump cycle and the outlet pump cycle is the pre-determined fraction ϕ.
The pre-determined fraction ϕ can be actively caused to change during the course of the method. For example, the pre-determined fraction ϕ could be set at a certain value for a first number of pump cycles, and set at a different value for a second number of pump cycles. Equally, as mentioned above, the device could be operated in a haemodialysis mode for a first number of pump cycles, and operated in a phase-delay convective operation method or a phase-advance convective operation method for a second number of pump cycles. The device could equally be operated in a conventional haemodiafiltration mode for a first number of pump cycles, and in a phase-delay convective operation method or a phase-advance convective operation method for a second number of pump cycles. Any sequence or combination of haemodialysis, phase-delay convective operation, phase-advance convective operation, or conventional haemodiafiltration may be possible.
Control of the operating method of the device may be through a closed loop control. A sensor, such as a pressure sensor, may be used to measure the pressure of the fluid at the outlet of the blood side of the dialyser. This may be indicative of the amount of fluid being removed from the blood at any given time, and may give an indication of haematocrit. This information can be used to control the pre-determined fraction ϕ during phased convective operation, or to change the method of operation of the device, for example to a haemodialysis mode. For example, if an indication that haematocrit level is too high, for example because too much fluid has been removed from the blood, then the device could reduce the pre-determined fraction ϕ, or change the pre-determined fraction ϕ to 0 such that haemodialysis is performed. This control could be affected manually or automatically through a programmed feedback operation.
Although a mechanism involving pumps driving the fluid is described, the inlet and outlet pump assemblies may be configured to allow different mechanisms for the phase-delay peaks.
One such mechanism involves the inlet pump assembly comprising an inlet pump 207 and the outlet pump assembly comprising an outlet valve 213. In this mechanism, the inlet pump 207 performs the dialysate delivery stroke, and the outlet valve 213 performs the dialysate removal stroke. In this mechanism, the outlet valve 213 operates in a similar manner to the outlet pump 216 operation described above. The inlet pump 207 may force fluid into the dialyser before the outlet valve 213 opens. Thus the mechanism utilises a single pump and a single valve.
Another such mechanism involves the inlet pump assembly comprising an inlet valve 209 and the outlet pump assembly comprising an outlet pump 216. In this mechanism, the inlet valve 209 performs the dialysate delivery stroke, and the outlet pump 216 performs the dialysate removal stroke. In this mechanism, the inlet valve 209 operates in a similar manner to the inlet pump 207 operation described above. The outlet pump 216 may start drawing fluid from the dialyser 12 before the inlet valve opens 209. Thus the mechanism utilises a single pump and a single valve.
Another such mechanism involves only an inlet pump 207 and an outlet pump 216 and no associated inlet or outlet valves 209, 213. In this mechanism, the inlet pump 207 performs the dialysate delivery stroke, and the outlet pump 216 performs the dialysate removal stroke. In this mechanism, as described previously, the inlet pump 207 delivery stroke may commence before the outlet pump 216 removal stroke commences. Equally, the inlet pump 207 delivery stroke may terminate before the outlet pump 216 removal stroke terminates.
It should be understood that, as described above, references to “operation of the device” do not require that the device is being operated in contact with a patient. There are various situations in which a blood treatment device could be operated in a phased convective operation which does not involve use for patient treatment. One example of such operation is during cleaning of the device. As outlined above, operating the device in a convective operation may clear particles or molecules that build up on the semi-permeable membrane of the dialyser. One other example of such operation is during a training exercise. One other example of such operation of the device is during calibration of the device.
It should be understood that various alternatives of the above-described embodiment may be possible.
One alternative to the device mechanism described in
One other alternative to the device mechanism described in
One other possible adaptation of the mechanism described above is that the pumps (termed “inlet” and “outlet” for clarity) may be swapped, so that the inlet pump 207 functions as an outlet pump 216 and the outlet pump 216 functions as an inlet pump 207. The terms “first” and “second” used to described the pumps with reference to
Although a specific form of blood treatment apparatus has been provided by way of example, it should be appreciated that the phased convective method is applicable to various forms of blood treatment apparatus. By way of example, although a blood treatment apparatus having a disposable cartridge has been described, the method may be used with a non-disposable cartridge, or a blood treatment device which does not have a cartridge. Although operation of pumps has been described by means of pneumatic pumps, it should be understood that there are various possible ways for the pumps and valves to be actuated. Non-limiting examples include hydraulic or mechanical actuation means. The pumps and valves used should not be limited to those comprising a flexible membrane. Any form of pump or valve may be appropriate, for example a volumetric pump.
Number | Date | Country | Kind |
---|---|---|---|
1701740 | Feb 2017 | GB | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/GB2018/050308 | 2/2/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2018/142153 | 8/9/2018 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2696173 | Thormod | Dec 1954 | A |
3338171 | Conklin et al. | Aug 1967 | A |
3468261 | Schmierer | Sep 1969 | A |
3605566 | Vetter | Sep 1971 | A |
3606592 | Madurski et al. | Sep 1971 | A |
3753493 | Mellor | Aug 1973 | A |
3774762 | Lichtenstein | Nov 1973 | A |
3807906 | Breit | Apr 1974 | A |
3921622 | Cole | Nov 1975 | A |
3972320 | Kalman | Aug 1976 | A |
4070725 | Cornelius | Jan 1978 | A |
4142845 | Lepp et al. | Mar 1979 | A |
4161264 | Malmgren | Jul 1979 | A |
4205686 | Harris et al. | Jun 1980 | A |
4353990 | Manske et al. | Oct 1982 | A |
4366061 | Papanek | Dec 1982 | A |
4368261 | Klose et al. | Jan 1983 | A |
4370983 | Lichtenstein | Feb 1983 | A |
4430048 | Fritsch | Feb 1984 | A |
4494912 | Pauliukonis | Jan 1985 | A |
D277991 | Becker | Mar 1985 | S |
4534755 | Calvert et al. | Aug 1985 | A |
4534756 | Nelson | Aug 1985 | A |
4546669 | Fischer et al. | Oct 1985 | A |
4564342 | Weber et al. | Jan 1986 | A |
4599165 | Chevallet | Jul 1986 | A |
4648869 | Bobo, Jr. | Mar 1987 | A |
4666598 | Heath et al. | May 1987 | A |
4710163 | Butterfield | Dec 1987 | A |
4771792 | Seale | Sep 1988 | A |
4828543 | Weiss et al. | May 1989 | A |
4897184 | Shouldice et al. | Jan 1990 | A |
D308249 | Buckley | May 1990 | S |
4969991 | Valadez | Nov 1990 | A |
5000664 | Lawless et al. | Mar 1991 | A |
5012197 | Seiffert et al. | Apr 1991 | A |
5032265 | Jha et al. | Jul 1991 | A |
5055198 | Shettigar | Oct 1991 | A |
5095910 | Powers | Mar 1992 | A |
5103211 | Daoud et al. | Apr 1992 | A |
5126831 | Nakagawara | Jun 1992 | A |
5232434 | Inagaki et al. | Aug 1993 | A |
5252213 | Ahmad et al. | Oct 1993 | A |
D341890 | Sievert et al. | Nov 1993 | S |
D344339 | Yoshikawa et al. | Feb 1994 | S |
5304349 | Polaschegg | Apr 1994 | A |
D347896 | Dickinson et al. | Jun 1994 | S |
D351470 | Scherer et al. | Oct 1994 | S |
5385540 | Abbott et al. | Jan 1995 | A |
5421823 | Kamen et al. | Jun 1995 | A |
5458468 | Ye et al. | Oct 1995 | A |
5476368 | Rabenau et al. | Dec 1995 | A |
5476792 | Ezrielev et al. | Dec 1995 | A |
D370979 | Pascale et al. | Jun 1996 | S |
5558347 | Nicholson | Sep 1996 | A |
5586872 | Skobelev et al. | Dec 1996 | A |
5586873 | Novak et al. | Dec 1996 | A |
5591344 | Kenley et al. | Jan 1997 | A |
5643201 | Peabody et al. | Jul 1997 | A |
5650071 | Brugger et al. | Jul 1997 | A |
5653456 | Mough | Aug 1997 | A |
5658456 | Kenley et al. | Aug 1997 | A |
5665307 | Kirschner et al. | Sep 1997 | A |
5727550 | Montecalvo | Mar 1998 | A |
D395085 | Kenley et al. | Jun 1998 | S |
5788851 | Kenley et al. | Aug 1998 | A |
5807322 | Lindsey et al. | Sep 1998 | A |
5882300 | Malinouskas et al. | Mar 1999 | A |
5948247 | Gillerfaik et al. | Sep 1999 | A |
5957670 | Duncan et al. | Sep 1999 | A |
5995910 | Discenzo | Nov 1999 | A |
6077443 | Goldau | Jun 2000 | A |
6126831 | Goldau et al. | Oct 2000 | A |
6132378 | Marino | Oct 2000 | A |
6143181 | Falkvall et al. | Nov 2000 | A |
6153102 | Kenley et al. | Nov 2000 | A |
6216029 | Paltieli | Apr 2001 | B1 |
6218329 | Singh et al. | Apr 2001 | B1 |
6251279 | Peterson et al. | Jun 2001 | B1 |
6261065 | Nayak et al. | Jul 2001 | B1 |
6303036 | Collins et al. | Oct 2001 | B1 |
6382923 | Gray | May 2002 | B1 |
6514462 | Simons | Feb 2003 | B1 |
6558347 | Jhuboo et al. | May 2003 | B1 |
6582206 | Schluecker | Jun 2003 | B2 |
6626832 | Paltieli et al. | Sep 2003 | B1 |
6626878 | Leisner et al. | Sep 2003 | B1 |
6645176 | Christenson et al. | Nov 2003 | B1 |
6663829 | Kjellstrand | Dec 2003 | B1 |
6733476 | Christenson et al. | May 2004 | B2 |
6743204 | Christenson et al. | Jun 2004 | B2 |
6801646 | Pena et al. | Oct 2004 | B1 |
6814547 | Childers et al. | Nov 2004 | B2 |
6967002 | Edgson et al. | Nov 2005 | B1 |
7040142 | Burbank | May 2006 | B2 |
7107837 | Lauman et al. | Sep 2006 | B2 |
7153286 | Busby et al. | Dec 2006 | B2 |
7220358 | Schacht et al. | May 2007 | B2 |
7284964 | McDowell et al. | Oct 2007 | B2 |
7383721 | Parsons et al. | Jun 2008 | B2 |
7434312 | Christenson et al. | Oct 2008 | B2 |
7494590 | Felding et al. | Feb 2009 | B2 |
7604398 | Akers et al. | Oct 2009 | B1 |
7648627 | Beden et al. | Jan 2010 | B2 |
7857976 | Bissier et al. | Dec 2010 | B2 |
7874999 | Busby | Jan 2011 | B2 |
7896197 | Furey et al. | Mar 2011 | B2 |
D641882 | Hickey et al. | Jul 2011 | S |
8114043 | Muller | Feb 2012 | B2 |
8132388 | Nagy et al. | Mar 2012 | B2 |
8137184 | Ajiro et al. | Mar 2012 | B2 |
8137300 | Han et al. | Mar 2012 | B2 |
8167431 | DeCusatis et al. | May 2012 | B2 |
8187184 | Muller et al. | May 2012 | B2 |
8192388 | Hogard | Jun 2012 | B2 |
8197431 | Bennison | Jun 2012 | B2 |
8221320 | Bouton | Jul 2012 | B2 |
8348850 | Frinak et al. | Jan 2013 | B2 |
8360977 | Marttila et al. | Jan 2013 | B2 |
8529490 | Warlar et al. | Sep 2013 | B2 |
8535522 | Fulkerson et al. | Sep 2013 | B2 |
8535525 | Heyes et al. | Sep 2013 | B2 |
D693469 | Chung et al. | Nov 2013 | S |
8597505 | Fulkerson et al. | Dec 2013 | B2 |
D702842 | Hyde et al. | Apr 2014 | S |
8685244 | Heyes et al. | Apr 2014 | B2 |
8696571 | Marttila et al. | Apr 2014 | B2 |
8708908 | Bouton | Apr 2014 | B2 |
8708946 | Han et al. | Apr 2014 | B2 |
D705432 | Lura et al. | May 2014 | S |
8798908 | Bourdeaut | Aug 2014 | B2 |
8801646 | Han et al. | Aug 2014 | B2 |
D714454 | Amemiya et al. | Sep 2014 | S |
D714946 | Lura et al. | Oct 2014 | S |
8926544 | Hogard et al. | Jan 2015 | B2 |
D724740 | Collins et al. | Mar 2015 | S |
8974394 | Frinak et al. | Mar 2015 | B2 |
9011334 | Bouton | Apr 2015 | B2 |
D735868 | Mareguddi et al. | Aug 2015 | S |
9220825 | Buckberry | Dec 2015 | B2 |
D781410 | Ritter et al. | Mar 2017 | S |
9744285 | Heyes et al. | Aug 2017 | B2 |
9833553 | Higgitt et al. | Dec 2017 | B2 |
10456516 | Heyes et al. | Oct 2019 | B2 |
D867597 | Bauer et al. | Nov 2019 | S |
10543305 | Buckberry et al. | Jan 2020 | B2 |
D879967 | Verguldi et al. | Mar 2020 | S |
D907211 | Spurling | Jan 2021 | S |
10881775 | Wallace | Jan 2021 | B2 |
10960120 | Wallace et al. | Mar 2021 | B2 |
D924410 | Mendoza et al. | Jul 2021 | S |
D938046 | Gupta et al. | Dec 2021 | S |
11365728 | Westenbrink | Jun 2022 | B2 |
11571499 | Milad et al. | Feb 2023 | B2 |
11583618 | Buckberry et al. | Feb 2023 | B2 |
20030217962 | Childers et al. | Nov 2003 | A1 |
20040195157 | Mullins et al. | Oct 2004 | A1 |
20040206703 | Bosetto et al. | Oct 2004 | A1 |
20040215129 | Edgson et al. | Oct 2004 | A1 |
20040223857 | Kline | Nov 2004 | A1 |
20050020961 | Burbank et al. | Jan 2005 | A1 |
20050205476 | Chevallet et al. | Sep 2005 | A1 |
20050209547 | Burbank et al. | Sep 2005 | A1 |
20050234384 | Westberg | Oct 2005 | A1 |
20060121623 | He et al. | Jun 2006 | A1 |
20070083193 | Werneth et al. | Apr 2007 | A1 |
20080006089 | Adnan et al. | Jan 2008 | A1 |
20080200865 | Bedingfield | Aug 2008 | A1 |
20080283096 | Scheringer et al. | Nov 2008 | A1 |
20090001245 | Childers et al. | Jan 2009 | A1 |
20090007642 | Busby et al. | Jan 2009 | A1 |
20090009290 | Kneip et al. | Jan 2009 | A1 |
20090012450 | Shah et al. | Jan 2009 | A1 |
20090012452 | Slepicka et al. | Jan 2009 | A1 |
20090012457 | Childers | Jan 2009 | A1 |
20090101550 | Muller et al. | Apr 2009 | A1 |
20090211975 | Brugger et al. | Aug 2009 | A1 |
20090230043 | Heyes et al. | Sep 2009 | A1 |
20100043694 | Patel | Feb 2010 | A1 |
20100045471 | Meyers | Feb 2010 | A1 |
20100089807 | Heyes et al. | Apr 2010 | A1 |
20100139254 | Sebestyen et al. | Jun 2010 | A1 |
20100263687 | Braun et al. | Oct 2010 | A1 |
20110009797 | Kelly et al. | Jan 2011 | A1 |
20110034850 | Jonsson | Feb 2011 | A1 |
20110132838 | Curtis et al. | Jun 2011 | A1 |
20110168614 | Pouchoulin et al. | Jul 2011 | A1 |
20120164022 | Muginstein et al. | Jun 2012 | A1 |
20120269907 | Coates | Oct 2012 | A1 |
20120276549 | Cunningham et al. | Nov 2012 | A1 |
20120292237 | Heyes et al. | Nov 2012 | A1 |
20120308431 | Kotsos et al. | Dec 2012 | A1 |
20130037465 | Heyes et al. | Feb 2013 | A1 |
20130056419 | Curtis | Mar 2013 | A1 |
20130153495 | Kelly et al. | Jun 2013 | A1 |
20130199998 | Kelly et al. | Aug 2013 | A1 |
20130274642 | Soykan et al. | Oct 2013 | A1 |
20140224736 | Heide | Aug 2014 | A1 |
20140251885 | Heyes | Sep 2014 | A1 |
20140271106 | Alessandro et al. | Sep 2014 | A1 |
20140299544 | Wilt et al. | Oct 2014 | A1 |
20150027951 | Wallace et al. | Jan 2015 | A1 |
20150076053 | Higgitt et al. | Mar 2015 | A1 |
20150112119 | Buckberry | Apr 2015 | A1 |
20150129481 | Higgitt et al. | May 2015 | A1 |
20150238673 | Gerber et al. | Aug 2015 | A1 |
20150258263 | Hogard | Sep 2015 | A1 |
20150352269 | Gerber et al. | Dec 2015 | A1 |
20150359954 | Gerber et al. | Dec 2015 | A1 |
20160045656 | Buckberry | Feb 2016 | A1 |
20160051743 | Buckberry | Feb 2016 | A1 |
20160058933 | Ballantyne et al. | Mar 2016 | A1 |
20160076535 | Clifton et al. | Mar 2016 | A1 |
20160077644 | Ritter et al. | Mar 2016 | A1 |
20160199558 | Buckberry | Jul 2016 | A1 |
20170056576 | Doyle et al. | Mar 2017 | A1 |
20170167983 | Klomp et al. | Jun 2017 | A1 |
20170252498 | Heyes et al. | Sep 2017 | A1 |
20170296730 | Soto et al. | Oct 2017 | A1 |
20180133391 | Heyes et al. | May 2018 | A1 |
20180154059 | Heyes et al. | Jun 2018 | A1 |
20180193545 | Crnkovich et al. | Jul 2018 | A1 |
20180344915 | Wallace | Dec 2018 | A1 |
20190001042 | Buckberry | Jan 2019 | A1 |
20190015577 | Garrido et al. | Jan 2019 | A1 |
20190024654 | May et al. | Jan 2019 | A1 |
20190358381 | Westenbrink | Nov 2019 | A1 |
20190376504 | Westenbrink | Dec 2019 | A1 |
20190385434 | Yuds et al. | Dec 2019 | A1 |
20200030515 | Merchant | Jan 2020 | A1 |
20200075159 | Bardorz et al. | Mar 2020 | A1 |
20200268958 | Heyes et al. | Aug 2020 | A1 |
20200276372 | Milad et al. | Sep 2020 | A1 |
20200330671 | Buckberry et al. | Oct 2020 | A1 |
20210110920 | Heyes et al. | Apr 2021 | A1 |
20220001087 | Heyes et al. | Jan 2022 | A1 |
20220160943 | Buckberry et al. | May 2022 | A9 |
20220241480 | Fincham | Aug 2022 | A1 |
20220241573 | Fincham | Aug 2022 | A1 |
Number | Date | Country |
---|---|---|
81430 | Aug 1997 | CA |
10024447 | Nov 2001 | DE |
0165751 | Dec 1985 | EP |
0754468 | Jan 1997 | EP |
2219703 | Aug 2010 | EP |
2955512 | Dec 2015 | EP |
004375764-0001 | Oct 2017 | EP |
004375764-0002 | Oct 2017 | EP |
007955125-0002 | Jun 2020 | EP |
2 310 136 | Dec 1976 | FR |
9007955125-0001 | May 2020 | GB |
9007955125-0002 | May 2020 | GB |
H04266740 | Sep 1992 | JP |
H06261872 | Sep 1994 | JP |
H07174659 | Jul 1995 | JP |
2000130334 | May 2000 | JP |
D1645323 | Nov 2020 | JP |
WO 8101800 | Jul 1981 | WO |
WO 9100113 | Jan 1991 | WO |
WO 9116542 | Oct 1991 | WO |
WO 9506205 | Mar 1995 | WO |
WO 9525893 | Sep 1995 | WO |
WO 9625214 | Aug 1996 | WO |
WO 9710013 | Mar 1997 | WO |
WO 9728368 | Aug 1997 | WO |
WO 9929356 | Jun 1999 | WO |
WO 2000006217 | Feb 2000 | WO |
WO 0057935 | Oct 2000 | WO |
WO 02066833 | Aug 2002 | WO |
WO 02081917 | Oct 2002 | WO |
WO 2003101510 | Dec 2003 | WO |
WO 2005044339 | May 2005 | WO |
WO 2005080794 | Sep 2005 | WO |
WO 2006120415 | Nov 2006 | WO |
WO 2006120417 | Nov 2006 | WO |
WO 2008100671 | Aug 2008 | WO |
WO 2008106191 | Sep 2008 | WO |
WO 2008135245 | Nov 2008 | WO |
WO 2009006489 | Jan 2009 | WO |
WO 2009024333 | Feb 2009 | WO |
WO 2009038834 | Mar 2009 | WO |
2009061608 | May 2009 | WO |
WO 2009127624 | Oct 2009 | WO |
WO 2010089130 | Aug 2010 | WO |
WO 2010146343 | Dec 2010 | WO |
WO 2011027118 | Mar 2011 | WO |
WO 2011068885 | Jun 2011 | WO |
WO 2011105697 | Sep 2011 | WO |
WO 2011105698 | Sep 2011 | WO |
WO 2013052680 | Apr 2013 | WO |
WO 2013057109 | Apr 2013 | WO |
2013110919 | Aug 2013 | WO |
WO 2013110906 | Aug 2013 | WO |
WO 2013114063 | Aug 2013 | WO |
WO 2013121162 | Aug 2013 | WO |
WO 2013121163 | Aug 2013 | WO |
WO 2014072195 | May 2014 | WO |
WO 2014082855 | Jun 2014 | WO |
WO 2014155121 | Oct 2014 | WO |
WO 2015007596 | Jan 2015 | WO |
2015022537 | Feb 2015 | WO |
WO 2016016870 | Feb 2016 | WO |
WO 2017137723 | Aug 2017 | WO |
WO 2018115816 | Jun 2018 | WO |
Entry |
---|
He et al., “A Fluorescent Sensor with High Selectivity and Sensitivity for Potassium in Water,” Journal of the American Chemical Society 2003 125 (6), 1468-1469. |
Kivi, Air Embolism, Healthline, Aug. 20, 2012, p. 1-5. |
Search Report and Written Opinion for International Application No. PCT/GB2018/050308, dated Apr. 26, 2018. |
Ergo-Express Motorized Dialysis Cart, Aug. 14, 2017, youtube.com [online], [site visited Jan. 9, 2022], Available from internet, URL: <https://www.youtube.com/watch?v=j4rAXthOmbY> (Year: 2017). |
Home Dialysis Tescon Aqua Tech, Aug. 1, 2020, youtube.com [online], [site visited Jan. 9, 2022], Available from internet, URL: <https://www.youtube.com/watch?v=WLLPZoS_mz4> (Year: 2020). |
LHO2028 Portable Hemodialysis Machine, date unknown, aliexpress.com [online], [site visited Jan. 4, 2022], Available from internet: <https ://www.aliexpress.com/item/1005003324875329.html?randl_currency=USD&_randl_shipto=US&src=google&afffcid=1003bab3b8db4e93b9ba88522a14cfc1-1641319351626-05232-UneMJZVf&aff_fsk=UneMJZVf&aff_platform=aaf&sk=UneMJZVf&aff_trace_key= (Year: 2022). |
Medical Hemodialysis Machine, date unknown, aliexpress.com [online], [site visited Jan. 4, 2022], Available from internet: <https://www.aliexpress.com/item/1005003445721549.html?_ randl_currency=USD&_randl_shipto=US&src=google&aff_fcid=a524f3f9cd9b4976b6b47962f3439d62-1641319166409-02691-UneMJZVf&aff_fsk=UneMJZVf&aff_platform=aaf&sk=UneMJZVf&aff_trace_key=a524f3f9cd9b4976b6b47962f3439d62-1641319166409-02691-UneMJZVf&terminal_id=d0c2cca4b7664d128cb4801 a9ef03ff2> (Year: 2022). |
Millenium HX Portable Dialysis Water System, Jul. 2, 2014, youtube.com [online], [site visited Jan. 10, 2022], Available from internet, URL: <https://www.youtube.com/watch?v=IGEbPi2CDsw> (Year: 2014). |
Portable home dialysis device, Nov. 2, 2017, med-technews.com [online], [site visited Jan. 4, 2022], Available from internet: <https://www.med-technews.com/news/portable-home-dialysis-device-to-launch-next-year/ (Year: 2017). |
Number | Date | Country | |
---|---|---|---|
20190374698 A1 | Dec 2019 | US |